Liu JY, Liang ZH, Liu JL, Li L, Cui B, Li TG. Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study. World J Psychiatry 2026; 16(4): 116158 [DOI: 10.5498/wjp.v16.i4.116158]
Corresponding Author of This Article
Jian-Yu Liu, MD, Associate Chief Physician, Department of Interventional Treatment, The 980th (Bethune International Peace) Hospital of the Joint Support Force of the Chinese People’s Liberation Army, No. 398 Zhongshan West Road, Qiaoxi District, Shijiazhuang 050082, Hebei Province, China. ljiany109527@163.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Apr 19, 2026 (publication date) through Mar 30, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liu JY, Liang ZH, Liu JL, Li L, Cui B, Li TG. Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study. World J Psychiatry 2026; 16(4): 116158 [DOI: 10.5498/wjp.v16.i4.116158]
World J Psychiatry. Apr 19, 2026; 16(4): 116158 Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.116158
Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study
Jian-Yu Liu, Zhi-Hui Liang, Jing-Lei Liu, Liang Li, Bao Cui, Tie-Gang Li
Jian-Yu Liu, Zhi-Hui Liang, Jing-Lei Liu, Liang Li, Bao Cui, Department of Interventional Treatment, The 980th (Bethune International Peace) Hospital of the Joint Support Force of the Chinese People’s Liberation Army, Shijiazhuang 050082, Hebei Province, China
Tie-Gang Li, Department of Oncology, The 980th (Bethune International Peace) Hospital of the Joint Support Force of the Chinese People’s Liberation Army, Shijiazhuang 050082, Hebei Province, China
Author contributions: Liu JY and Liang ZH were the guarantors and designed the study; Liu JY, Liang ZH, and Liu JL participated in the acquisition, analysis, and interpretation of the data and drafted the initial manuscript; Li L, Cui B, and Li TG revised the article critically for important intellectual content; all the authors participated in this study and jointly reviewed and edited the manuscript.
Supported by 2023 Hebei Provincial Medical Scientific Research Project Plan, No. 20231304.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the 980th (Bethune International Peace) Hospital of the Joint Support Force of the Chinese People’s Liberation Army (Approval No. BIPH-2022-KY-011).
Clinical trial registration statement: This study involved no randomization or investigational intervention; therefore, clinical trial registration was not required.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflicts of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: There are no additional data available.
Corresponding author: Jian-Yu Liu, MD, Associate Chief Physician, Department of Interventional Treatment, The 980th (Bethune International Peace) Hospital of the Joint Support Force of the Chinese People’s Liberation Army, No. 398 Zhongshan West Road, Qiaoxi District, Shijiazhuang 050082, Hebei Province, China. ljiany109527@163.com
Received: November 21, 2025 Revised: December 20, 2025 Accepted: January 12, 2026 Published online: April 19, 2026 Processing time: 128 Days and 23 Hours
Core Tip
Core Tip: This study investigated the impact of drug-eluting microsphere - transcatheter arterial chemoembolization (DEM-TACE) combined with lenvatinib on anxiety, depression, and quality of life (QoL) in patients with hepatocellular carcinoma (HCC). Among 126 enrolled patients, the prevalence of anxiety and depression significantly decreased over 12 months, accompanied by marked improvements in global health and functional scores on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and Quality of Life Questionnaire-Hepatocellular Carcinoma 18. The combination therapy showed favorable tumor response and manageable toxicity. These findings highlight the dual benefits of DEM-TACE plus lenvatinib in improving both psychological well-being and overall QoL in HCC management.
